BioPharma Ambition

ASCO urges industry to share real-world data for clinical trial efficiency

By Flora Southey

- Last updated on GMT

(Image: Getty/Bogdanhoda)
(Image: Getty/Bogdanhoda)
Sharing real-world data between CROs, sponsors and academic institutions will help improve trial design, says cancer association.

“Conventional clinical trials are becoming obsolete,” ​American Society of Clinical Oncology (ASCO) executive Richard Schilsky told delegates last month, arguing that an increasing number of cancer drugs and indications​ is forcing the industry to re-think clinical trials.

With more than 800 new cancer drugs in development – many of which target rare genotypes – it is no longer possible to conduct randomized clinical trials in every population, said Schilsky at the BioPharma Ambition Conference in Dublin, Ireland.

“We cannot learn everything that remains to be learned about all the various subtypes of cancer, by doing individual, prospective clinical trials about each subtype.

“We have to rethink the way we do clinical trials, in order to design clinical trials that are appropriate for the patient populations and the biology that we're trying to study,” ​he said. 

As a result, Schilsky urged delegates collect and share information over the entire lifecycle of the drug: “Learning needs to combine trial data and real-world data.”

The executive argued that firms do not need to know everything they eventually would like to know about a drug, at the time of market entry. While there is certain information required in order to justify market entry, there is a lot of information that can be developed about the drug in the post-market phase, he said.

Related news

Show more

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers